Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288
01/06/2026 08:00 PM • Ascentage Pharma received FDA IND clearance for APG-3288, a novel BTK-targeted protein degrader using PROTAC technology, to treat relapsed/refractory B-cell malignancies. The drug is designed to degrade BTK proteins rather than inhibit them, potentially overcoming resistance to existing BTK inhibitors and representing a major pipeline expansion for the company.
AAPG - The company achieved FDA IND clearance for a novel BTK degrader candidate, marking a significant milestone in clinical development and pipeline expansion. The drug demonstrates differentiated mechanisms with potential advantages over existing BTK inhibitors, including ability to overcome resistance mutations. This represents meaningful progress in the company's oncology portfolio and validates their PROTAC technology platform.